Serina Therapeutics
Business Services · Alabama, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
601 Genome Way Ste 2001, Huntsville, Ala...Phone Number
(256) 327-0548Website
www.serinatx.comRevenue
-Stock Symbol
SERIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252.Explore more
Serina Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Serina Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Serina Therapeutics had a recent Job posting/layoffs
Check if Serina Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Serina Therapeutics launches new products
Funding: Get notified immidiatlly once Serina Therapeutics has new funding data
Check out if Serina Therapeutics is spiking on competitors!
Earning: See what the market has to say on Serina Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Serina Therapeutics
Serina Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Serina Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Serina Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Serina Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Serina Therapeutics.
Serina Therapeutics financials insights
Gather financial insights about Serina Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$4.9M
2017
Private Equity
$8M
2020
Debt
$150K
2022
Series B
$5M
2024
Private Equity
$10M
2025
Share Placement
$5M
Stock/Share Issuance
$20M
2026
Stock/Share Issuance
$30M
Stock/Share Issuance
$25M
Serina Therapeutics Tech Stack
A closer look at the technologies used by Serina Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Person-Based
Employee Relations, Contracts, HR Operations
Person-Based
Person-Based
Partnership, Research & Development
Serina Therapeutics News & Media
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data –Serina Therapeutics secures $25M equity financing facility with Roth Principal | Dealroom.co
Serina Therapeutics has secured a $25 million equity financing facility with Roth Principal Investments through a Common Stock Purchase Agreement dated 21 August 2026. The agreement allows Serina to sell up to $25 million of newly issued common stock over 36 months, though the company is not obligated to sell any shares. Under the facility, Serina can direct Roth to purchase shares at a 3% to 7% discount to the volume-weighted average price, depending on purchaseSerina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Serina Therapeutics
Sign Up For FreeTo access detailed company insights
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanopar... Read More
